New Market - May 22, 2018
AstraZeneca’s Lokelma approved in the US
The US Food and Drug Administration has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults with hyperkalaemia,a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases. The risk of hyperkalaemia increases significantly for patients with chronic kidney disease (CKD) and for those who take common […]
New Market - April 5, 2018
Novo’s Ozempic approved in Japan
Novo Nordisk has announced that the Japanese Ministry of Health, Labour and Welfare has approved Ozempic (semaglutide), a new once-weekly analogue of human glucagon-like peptide-1 (GLP-1), for the treatment of adults with type 2 diabetes. The approval of Ozempic in Japan is based on results from the SUSTAIN clinical trial programme, which involved more than […]
New Market - March 31, 2018
AstraZeneca’s Lokelma approved in the EU
The European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia. Hyperkalaemia is a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases. Lokelma is a highly-selective, oral potassium-removing agent. The approval is supported by data from three double-blind, placebo-controlled […]
New Market - March 15, 2018
NDA Group opens office in Paris
The drug development consultancy announces the opening of a Paris office to serve its increasing French customer base and in continuation of its strategic global expansion. This is NDA’s fifth European location, having offices in Stockholm, London, Munich and Zürich. The Paris office will complement the existing capabilities in other European offices to support more […]
Biotech Business - February 7, 2018
Spherotide to the Chinese market
Xbrane Biopharma and China Resource Pharmaceutical Group Limited have entered into a license agreement which gives CR Pharma exclusive rights to market and sell Spherotide (Triptorelin, a GnRH analogue in a parenteral depot formulation) in China. Swedish Xbrane will receive a license fee in high single digit million USD range paid upon signing and on milestones […]
New Market - January 22, 2018
First US order for ScandiDos
The company has received the first order for its Delta4 Discover system in the United States from The University Medical Center in Lubbock, Texas “We serve our community and safety is not just a promise, it is a priority. We look forward to informing our community that our continuing efforts to ensure safe radiation treatments have reached a new pinnacle with […]
